Progress in lung cancer: ASCO 2015-Reference-Cited by-同舟云学术

Progress in lung cancer: ASCO 2015

Published:2015-12 Issue:4 Volume:24 Page:367-368
ISSN:0960-7404
Container-title:Surgical Oncology
language:en
Short-container-title:Surgical Oncology

Author:

Masters Gregory A.

Publisher

Elsevier BV

Subject

Oncology,Surgery

Reference8 articles.

1. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

2. Trimodality therapy in the treatment of stage IIIA non-small cell lung cancer (NSCLC): analysis of the National Cancer Database;Behera;J. Clin. Oncol.,2015

3. AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): results from a phase 1 expansion cohort;Ramalingam;J. Clin. Oncol.,2015

4. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

5. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC);Paz-Ares;J. Clin. Oncol. (Meeting Abstracts),2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a single population?;PLOS ONE;2020-05-12

2. Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14;Cancer Letters;2018-07